DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial

DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases

(2014) Julie E. Ledgerwood et al.   Human vaccines & immunotherapeutics

DNA Priming Prior to Inactivated Influenza A(H5N1) Vaccination Expands the Antibody Epitope Repertoire and Increases Affinity Maturation in a Boost-Interval–Dependent Manner in Adults

(2013) Surender Khurana et al.   JOURNAL OF INFECTIOUS DISEASES

Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect

(2013) Julie E. Ledgerwood, Kathryn Zephir, Zonghui Hu, Chih-Jen Wei, LeeJah Chang, Mary E. Enama, Cynthia S. Hendel, Sandra Sitar, Robert T. Bailer, Richard A. Koup, John R. Mascola, Gary J. Nabel, Barney S. Graham et al.   JOURNAL OF INFECTIOUS DISEASES

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

(2011) Julie E Ledgerwood et al.   LANCET INFECTIOUS DISEASES

Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination

(2010) C.-J. Wei et al.   SCIENCE

Multivalent HA DNA Vaccination Protects against Highly Pathogenic H5N1 Avian Influenza Infection in Chickens and Mice

(2008) Srinivas Rao et al.   PLoS One